Evidence map›Paper›PMID 38000171›Full record

ArticleJournal of photochemistry and photobiology. B, Biology2024

Immunofluorescence profiling of collagen subtypes is a predictor of treatment outcomes in pancreatic cancer.

Girgis Obaid, Menitte Eroy, Jie Zhao, Shazia Bano, Mari Mino-Kenudson, Tayyaba Hasan

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of photochemistry and photobiology. B, Biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Glutamine-dependent changes in fibroblast-derived extracellular matrix dictate cancer cell behavior.Matrix biology : journal of the International Society for Matrix Biology · 2026
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Girgis ObaidDepartment of Bioengineering, University of Texas at Dallas, Richardson, TX 75080, USA; Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Menitte EroyDepartment of Bioengineering, University of Texas at Dallas, Richardson, TX 75080, USA.
Jie ZhaoMassachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Shazia BanoMassachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Mari Mino-KenudsonMassachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Tayyaba HasanMassachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Division of Health Sciences and Technology, Harvard University and Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address: thasan@mgh.harvard.edu.
Harvard University · USMassachusetts General Hospital · USMassachusetts Institute of Technology · USThe University of Texas at Dallas · US

Funding

Small Molecule Enhancers of Photodynamic Therapy for Skin CancerP01CA084203 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Tayyaba Hasan · 2001 to 2026
$27.9M
Targeted Photoactivable Nanocells: Image-based Drug Delivery and Dosimetry in GBMR01CA156177 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA, POGUE, BRIAN WILLIAM · 2011 to 2015
$2.5M
Ovarian Cancer PDT: Multi-intracellular targeting and Image-guided dosimetryR01CA160998 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA · 2011 to 2015
$2.0M
Molecular imaging-directed bioengineering of nanoconjugates as adaptable tumor targeting platformsR00CA215301 · NCI · UNIVERSITY OF TEXAS DALLAS · PI OBAID, GIRGIS · 2020 to 2022
$721k
Molecular imaging-directed bioengineering of nanoconjugates as adaptable tumor targeting platformsK99CA215301 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI OBAID, GIRGIS · 2018 to 2019
$358k
NCI NIH HHS K99 CA215301NCI NIH HHS P01 CA084203NCI NIH HHS R00 CA215301NCI NIH HHS R01 CA156177NCI NIH HHS R01 CA160998
6 · The paper itself

Abstract

Desmoplasia in pancreatic ductal adenocarcinoma (PDAC) is characterized by elevated levels of tumor collagen. Desmoplasia restricts drug delivery in PDAC, contributes to treatment resistance, and is associated with poor survival outcomes. We have previously shown that photodynamic therapy (PDT)-based treatment remediates desmoplasia in orthotopic PDAC tumors by reducing second harmonic generation signals from collagen by >90% and by reducing collagen alignment by >10

Indexed as

Pancreatic NeoplasmsAnimalsCollagenCollagen Type IFluorescent Antibody TechniqueHumansLiposomesMiceTreatment OutcomeCollagenCollagen Type ILiposomesCollagenDesmoplasiaImmunofluorescenceNanomedicinePancreatic cancerPhotodynamic therapySubtypes

Identifiers

PMID38000171
PMCPMC10841621
OpenAlexW4388294651

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.